P-242 Comprehensive assessment of systemic and local immunity and clinical indicators in patients with gastric cancer

Gastric cancer (GC) ranks 5th among oncology diseases (1,313,000 cases) and is the 3rd cause of death from (819,000 deaths) in world. Currently, there no doubt that a malignant tumor dynamic system, considered combination with all morphological components form its microenvironment: stromal cells, cells immune blood lymph vessels, extracellular matrix. The predictive value systemic inflammatory indices based on calculation ratios neutrophils, lymphocytes platelets peripheral patients colorectal cancer, gastric hepatocellular makes it possible to use these indicators clinical practice at stage planning complex treatment neoplasms, as early identify signs relapse disease. An important step development new therapeutic agents was understanding role prognostic factors, including significance subpopulation composition immunocompetent biology. From 2017 2018 N.N. Blokhin NMRC Oncology, 45 primary adenocarcinoma (25 - stages I – III, 20 IV) received surgical/combined or chemotherapy, respectively. Peripheral tissue were collected before starting treatment. percentage degree infiltration by (CD45+CD14-TILs) assessed flow cytometry; T (CD3+CD19-TILs); B (CD3-CD19+TILs); NK (CD3-CD16+CD56+TILs); effector CD16 CD8 their cytotoxic potential (CD16+Perforin+TILs; CD16CTPTILs), (CD8+Perforin+TILs; CD8CTPTILs); subpopulations regulatory cells- NKT (CD3+CD16+CD56+TILs), CD4 (CD4+CD25+CD127-TILs) (CD8+CD11b-CD28-TILs) parameters immunity. Intratumoral CD4+TILs, CD8+TILs, CD4+/CD8+TILs studied immunohistochemistry. Also, cellular investigated. inflammation factors (neutrophil-lymphocyte index, platelet-lymphocyte index) characteristics (patient's age (both years groups: up years, 46-60 over 60 years), disease stage, differentiation (G), Lauren type, MSI status for overall survival (OS) progression-free (PFS). factor favorable prognosis PFS local locally advanced forms an increase number CD3+CD19-TILs (HR0.865,95%CI0.782–0.957, p=0.005), poor cells; HR1.382,95%CI1.087–1.758, p=0.008. There negative effect relative content level neutrophils OS metastatic GC (HR1.42,95%CI1.06-1.89, p=0.017 HR1.64,95%CI1.12–2.40,p=0.011). At same time, patients, (HR1.106, 95%CI1.002-1.199, p=0.015; HR1.714, 95%CI1.063-2.764, p=0.027 HR1.017,95%CI1.006-1.029, p=0.003) reduced cancer. Indicators immunity, blood, characterizing response, well immunity can serve additional